JP2010507650A - 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用 - Google Patents

自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用 Download PDF

Info

Publication number
JP2010507650A
JP2010507650A JP2009534061A JP2009534061A JP2010507650A JP 2010507650 A JP2010507650 A JP 2010507650A JP 2009534061 A JP2009534061 A JP 2009534061A JP 2009534061 A JP2009534061 A JP 2009534061A JP 2010507650 A JP2010507650 A JP 2010507650A
Authority
JP
Japan
Prior art keywords
disease
thymosin alpha
treatment
ibd
colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009534061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507650A5 (enExample
Inventor
ロマーニ、ルイジーナ
ビストーニ、フランチェスコ
ガラチ、エンリコ
ラシ、グイード
ヴァッレボーナ、パオラ シニバルディ
Original Assignee
シグマ − タウ インデュストリエ ファーマシューティッツェ リウニーテ ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグマ − タウ インデュストリエ ファーマシューティッツェ リウニーテ ソシエタ ペル アチオニ filed Critical シグマ − タウ インデュストリエ ファーマシューティッツェ リウニーテ ソシエタ ペル アチオニ
Publication of JP2010507650A publication Critical patent/JP2010507650A/ja
Publication of JP2010507650A5 publication Critical patent/JP2010507650A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009534061A 2006-10-27 2007-09-27 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用 Pending JP2010507650A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000584A ITRM20060584A1 (it) 2006-10-27 2006-10-27 Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni
PCT/IT2007/000677 WO2008050363A2 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2010507650A true JP2010507650A (ja) 2010-03-11
JP2010507650A5 JP2010507650A5 (enExample) 2010-11-11

Family

ID=39322489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009534061A Pending JP2010507650A (ja) 2006-10-27 2007-09-27 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用

Country Status (13)

Country Link
US (1) US20100004174A1 (enExample)
EP (1) EP2086569A2 (enExample)
JP (1) JP2010507650A (enExample)
KR (1) KR20090096688A (enExample)
CN (1) CN101534853A (enExample)
AU (1) AU2007310416A1 (enExample)
BR (1) BRPI0718010A2 (enExample)
CA (1) CA2666609A1 (enExample)
EA (1) EA200900602A1 (enExample)
IL (1) IL198291A0 (enExample)
IT (1) ITRM20060584A1 (enExample)
MX (1) MX2009004196A (enExample)
WO (1) WO2008050363A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100248272A1 (en) * 2009-03-31 2010-09-30 Cornell University Method for identifying Smk box riboswitch modulating compounds
WO2025078961A1 (en) * 2023-10-13 2025-04-17 Gufic Biosciences Limited Composition and method for treatment of endometriosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
WO1995011696A1 (en) * 1993-10-26 1995-05-04 Alpha 1 Biomedicals, Inc. Composition for the treatment of autoimmune hepatitis containing thymosin alpha i and a corticosteroid
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
CN1198950A (zh) * 1998-04-24 1998-11-18 崔泊 一种结肠炎新药的制备
CN1628796A (zh) * 2004-08-20 2005-06-22 康合堂 一种治疗溃疡性结肠炎的药物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
WO1995011696A1 (en) * 1993-10-26 1995-05-04 Alpha 1 Biomedicals, Inc. Composition for the treatment of autoimmune hepatitis containing thymosin alpha i and a corticosteroid
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012039259; 金井隆典，渡辺守: Ｊｐｎ．　Ｊ．　Ｃｌｉｎ．　Ｉｍｍｕｎｏｌ． ｖｏｌ．２７，　Ｎｏ．５, 2004, ｐ．３０２-３０８ *
JPN6012039261; Ｌ．Ｒｏｍａｎｉ　ｅｔ　ａｌ．: Ｂｌｏｏｄ ｖｏｌ．１０８，　Ｎｏ．７, 20061001, ｐ．２２６５-２２７４ *

Also Published As

Publication number Publication date
WO2008050363A8 (en) 2009-06-04
WO2008050363A2 (en) 2008-05-02
MX2009004196A (es) 2009-06-30
WO2008050363A3 (en) 2008-06-26
CA2666609A1 (en) 2008-05-02
CN101534853A (zh) 2009-09-16
EA200900602A1 (ru) 2009-10-30
IL198291A0 (en) 2011-08-01
BRPI0718010A2 (pt) 2013-11-19
EP2086569A2 (en) 2009-08-12
US20100004174A1 (en) 2010-01-07
KR20090096688A (ko) 2009-09-14
AU2007310416A1 (en) 2008-05-02
ITRM20060584A1 (it) 2008-04-28

Similar Documents

Publication Publication Date Title
Ridge et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone
Handley et al. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study.
Liversidge et al. Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis
Chen et al. Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells
He et al. SOCS1 mimetic peptide suppresses chronic intraocular inflammatory disease (Uveitis)
KR101951787B1 (ko) mTOR 저해제를 함유하는 황반변성 치료용 의약조성물
Olivieri et al. Role of bromhexine in exacerbations of bronchiectasis: double-blind randomized multicenter study versus placebo
JP7421219B2 (ja) 炎症性サイトカインを阻害するための医薬組成物
Bhathal et al. Primary intrahepatic obliterating cholangitis: a possible variant ofsclerosing cholangitis'
JP2023126760A (ja) 抗炎症剤
He et al. Amygdalin ameliorates alopecia areata on C3H/HeJ mice by inhibiting inflammation through JAK2/STAT3 pathway
KR101620341B1 (ko) 염증성장질환 및 1형 당뇨병치료를 위한 ａｐｌ 펩티드의 사용
KR102174191B1 (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
CN115052613B (zh) 包含肽或肽混合物作为活性成分的组合物及其医疗用途
JP2010507650A (ja) 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用
KR20030035047A (ko) Bmp-4 유전자 발현을 이용한 편평태선 질환의 치료 및진단방법
CN119606971A (zh) Vbit-4或其药学上可接受的盐在制备预防或治疗白癜风及其并发症的药物中的应用
Akpek et al. Herpes zoster sine herpete presenting with hyphema
CN1218405A (zh) 用肿瘤坏死因子-α治疗囊肿病
JP4333901B2 (ja) リウマチ関節炎治療用プロディギオシン組成物
Kar et al. Mycobacterial infections
Pan et al. Angelicin alleviates sepsis-associated encephalopathy via inhibition of IKK2 and the NF-κB pathway
HK1137651A (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases
WO2018048046A2 (ko) mTOR 저해제를 함유하는 황반변성 치료용 의약조성물
CN108451949A (zh) 芍药苷代谢素i在制备治疗结肠炎药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130108